Skip to main content
CHRS
NASDAQ Life Sciences

Coherus Q3 Revenue Misses; Cuts ~30% of Staff, Narrows Pipeline to Esophageal Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.798
Mkt Cap
$126.32M
52W Low
$0.732
52W High
$2.616
52W Position info
9.0% above low
Off High info
70% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

CHRS is trading near its 52-week low of $0.732 (9.0% above the low).

Summary

Coherus reported Q3 revenue of $14.274M, missing estimates, and announced a strategic prioritization plan that cuts headcount ~30% and focuses tagmokitug on esophageal cancer, lowering quarterly core cash burn by $6-7M.


Key Events · Earnings and Guidance · CHRS

  • Q3 Revenue Misses Consensus

    Net revenue came in at $14.274 million versus roughly $16 million expected, an ~11% miss, though up 25% from $11.2 million in Q3 2025.

  • ~30% Headcount Reduction

    The strategic prioritization plan right-sizes the organization, cutting headcount by approximately 30% and lowering core cash burn by $6 million to $7 million quarterly.

  • Pipeline Narrowed to Esophageal Cancer

    Tagmokitug/toripalimab development is focused on esophageal cancer with plans for an expedited path, initially second-line; other tagmokitug-toripalimab cohorts are deprioritized.

  • Cash Runway Still Tight

    Cash, cash equivalents and marketable securities totaled $83.6 million at September 30, 2026, down from $172.1 million at December 31, 2025, against a $38.9 million Q3 net loss from continuing operations.


Analysis · CHRS · Life Sciences

The Q3 revenue miss ($14.274M vs ~$16M consensus) is being met with a real restructuring: about 30% of headcount goes, tagmokitug development narrows to esophageal cancer, and core cash burn drops by $6-7M per quarter. That lowers the LOQTORZI revenue needed to cover core burn to $25-30M quarterly from the prior $30-35M guide — meaningful because LOQTORZI did $14.0M this quarter. With $83.6M of cash against a $38.9M quarterly net loss, the runway math still points to more capital raises; the $50M ATM with Leerink filed in August is the likely source.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CHRS was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.3M. The 52-week trading range was $0.73 to $2.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CHRS - Latest Insights

CHRS
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8008
Real-time Price: $0.8215 info
Change: +$0.0207 (+3%) info
Market Cap: $126.32M info
CHRS
Nov 09, 2026, 4:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.8215 info
Change: +$0.0515 (+7%) info
Market Cap: $126.32M info
CHRS
Oct 29, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.8215 info
Change: -$0.2285 (-22%) info
Market Cap: $126.32M info
CHRS
Sep 23, 2026, 1:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.8215 info
Change: -$0.4235 (-34%) info
Market Cap: $126.32M info
CHRS
Aug 17, 2026, 5:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.8215 info
Change: -$0.4085 (-33%) info
Market Cap: $126.32M info